This is a working overview of lipogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-16 and is reviewed periodically as new material appears.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Insulin secretion === Individuals with type 2 diabetes, which accounts for 90% of all diabetes cases, have decreases in the proliferation, maturation, and activity of their pancreatic islet insulin-secreting beta-cells as well as the potency of insulin's actions. These decreases result in reduced insulin secretion, hyperglycemia, and the many other afflictions associated with this disorder. Studies in the past have reported that the activation of FFAR3 reduced the insulin secreted by (1) human and mouse beta cells in vivo, (2) cultured human and murine beta cell-containing pancreatic islets, and (3) cultured beta cell lines. These studies showed that acetic acid-induced inhibition of insulin secretion by mouse pancreatic islets did not occur in islets that had both of their Ffar3 and Ffar2 genes knocked out but had no effect on insulin secretion in islets that had only one of the two genes knocked out.
1905: American geneticist Nettie Stevens discovered sex chromosomes. 1906: Following the San Francisco earthquake, American botanist and curator Alice Eastwood rescued almost 1500 rare plant specimens from the burning California Academy of Sciences building. Her curation system of keeping type specimens separate from other collections – unconventional at the time – allowed her to quickly find and retrieve the specimens. 1906: Russian chemist Irma Goldberg published a paper on two newly discovered chemical reactions involving the presence of copper and the creation of a nitrogen-carbon bond to an aromatic halide. These reactions were subsequently named the Goldberg reaction and the Jourdan-Ullman-Goldberg reaction. 1906: English physicist, mathematician and engineer Hertha Ayrton became the first female recipient of the Hughes Medal from the Royal Society of London. She received the award for her experimental research on electric arcs and sand ripples. 1906: After her death, English lepidopterist Emma Hutchinson's collection of 20,000 butterflies and moths was donated to the London Natural History Museum. She had published little during her lifetime, and was barred from joining local scientific societies due to her gender, but was honoured for her work when a variant form of the comma butterfly was named hutchinsoni. 1907: Swedish-Norwegian physicist and nutritionist Signe Schmidt-Nielsen became one of the first women in Sweden to receive a doctoral degree. She was also the first woman to become a member of the Royal Norwegian Society of Sciences and Letters.
Highland Council announces that Inverness's Hogmanay celebration will not take place in 2024–25 due to capacity and rising costs. 23 August – Edinburgh City Council votes to introduce a temporary fireworks ban around Bonfire Night in the city's Niddrie, Balerno, Seafield and Calton Hill districts, becoming the first Scottish council to implement such a ban. 25 August – BBC Scotland News reports that Scotland's local authorities are to divert money used to restore nature projects to pay for wage increases. 26 August – ASLEF suspends planned strike action for ScotRail drivers following a new pay offer, and will ballot its members on the offer. The Scottish Government confirms it will suspend the Connecting Scotland programme which provides iPads and laptops to people who are "digitally excluded" in order to pay for council pay rises. 28 August – Justice Secretary Angela Constance confirms that around 470 prisoners have been released under emergency provisions to release prisoners early from their sentences. 30 August – Cheyenne Naeb, an American philosophy student at the University of Dundee, who pushed a female member of railway staff in front of a stationary train at Glasgow Queen Street railway station in February 2023 after missing his train, is sentenced to 20 months in prison at Glasgow Sheriff Court. During a closed-door session at the SNP Party Conference, leader John Swinney tells delegates the party's losses at the election occurred because it spent too much time focusing on the "process of independence".
In mammals, when a muscle contracts, a series of reactions occur. Muscle contraction is stimulated by the motor neuron sending a message to the muscles from the somatic nervous system. Depolarization of the motor neuron results in neurotransmitters being released from the nerve terminal. The space between the nerve terminal and the muscle cell is called the neuromuscular junction. These neurotransmitters diffuse across the synapse and bind to specific receptor sites on the cell membrane of the muscle fiber. When enough receptors are stimulated, an action potential is generated and the permeability of the sarcolemma is altered. This process is known as initiation.
The species was first described by Elias Magnus Fries as Agaricus semilanceatus in his 1838 work Epicrisis Systematis Mycologici. Paul Kummer transferred it to Psilocybe in 1871 when he raised many of Fries's sub-groupings of Agaricus to the level of genus. Panaeolus semilanceatus, named by Jakob Emanuel Lange in both 1936 and 1939 publications, is a synonym. According to the taxonomical database MycoBank, several taxa once considered varieties of P. semilanceata to be synonymous with the species now known as Psilocybe strictipes: the caerulescens variety described by Pier Andrea Saccardo in 1887 (originally named Agaricus semilanceatus var. coerulescens by Mordecai Cubitt Cooke in 1881), the microspora variety described by Rolf Singer in 1969, and the obtusata variety described by Marcel Bon in 1985. Several molecular studies published in the 2000s demonstrated that Psilocybe, as it was defined then, was polyphyletic. The studies supported the idea of dividing the genus into two clades, one consisting of the bluing, hallucinogenic species in the family Hymenogastraceae, and the other the non-bluing, non-hallucinogenic species in the family Strophariaceae. However, the generally accepted lectotype (a specimen later selected when the original author of a taxon name did not designate a type) of the genus as a whole was Psilocybe montana, which is a non-bluing, non-hallucinogenic species. If the non-bluing, non-hallucinogenic species in the study were to be segregated, it would have left the hallucinogenic clade without a valid name.
Sources: en.wikipedia.org
==== Breast cancer ==== In combination with low doses of herceptin, selective ADAM10 inhibitors decrease proliferation in HER2 over-expressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact. These results are consistent with ADAM10 being a major determinant of HER2 shedding, the inhibition of which, may provide a novel therapeutic approach for treating breast cancer and a variety of other cancers with active HER2 signaling. The presence of the product of this gene in neuronal synapses in conjunction with protein AP2 has been seen in increased amounts in the hippocampal neurons of Alzheimer's disease patients.
Spectroscopy measures the interaction of the molecules with electromagnetic radiation. Spectroscopy consists of many different applications such as atomic absorption spectroscopy, atomic emission spectroscopy, ultraviolet-visible spectroscopy, X-ray fluorescence spectroscopy, infrared spectroscopy, Raman spectroscopy, nuclear magnetic resonance spectroscopy, photoemission spectroscopy, Mössbauer spectroscopy, and circular dichroism spectroscopy.
Jesus himself identifies John as "Elijah who is to come", which is a direct reference to the Book of Malachi (Malachi 4:5), that has been confirmed by the angel who announced John's birth to his father, Zechariah. According to the Gospel of Luke, John and Jesus were relatives. Saint George was a Christian who is venerated as a saint in Christianity, and he was a soldier of Cappadocian Greek origin and member of the Praetorian Guard for Roman emperor Diocletian, who was sentenced to death for refusing to recant his Christian faith. He became one of the most venerated saints and megalomartyrs in Christendom, and he has been especially venerated as a military saint since the Crusades. In hagiography, as one of the Fourteen Holy Helpers and one of the most prominent military saints, he is immortalized in the legend of Saint George and the Dragon. His memorial, Saint George's Day, is traditionally celebrated on 23 April. England, Ethiopia, Georgia, Catalonia and Aragon in Spain, Moscow in Russia, and several other states, regions, cities, universities, professions and organizations claim George as their patron. The bones of Saint George are buried in the Church of Saint George, Lod, Israel.
==== "FDA-Cleared" vs "FDA-Approved" ==== Clearance requests are required for medical devices that prove they are "substantially equivalent" to the predicate devices already on the market. Approved requests are for items that are new or substantially different and need to demonstrate "safety and efficacy", for example they may be inspected for safety in case of new toxic hazards. Both aspects need to be proved or provided by the submitter to ensure proper procedures are followed.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.